99 research outputs found
Infective endocarditis in bicuspid aortic valve and mitral valve prolapse.
Background: There is little information concerning infective endocarditis (IE) in patients with bicuspid aortic valve (BAV) / mitral valve prolapse (MVP), and IE antibiotic prophylaxis (IEAP) is currently not recommended for these conditions.
Objectives: To describe the clinical and microbiological features of IE in patients with BAV and MVP and compare them with those of IE patients with and without IEAP indication, to determine the potential benefit of IEAP in these conditions.
Methods: This analysis involved 3,208 consecutive IE patients prospectively included in the GAMES registry at 31 Spanish hospitals. Patients were classified as high-risk IE with IEAP indication (high-risk group; n=1,226), low and moderate-risk IE without IEAP indication (low/moderate-risk group; n=1,839), and IE with BAV (n=54) or MVP (n=89).
Results: BAV and MVP patients had a higher incidence of viridans group Streptococci (VGS) IE than high-risk group and low/moderate-risk group patients (35.2% and 39.3% vs 12.1% and 15%, respectively, all p<0.01). A similar pattern was seen for IE from suspected odontological origin (14.8% and 18% vs 5.8% and 6%, all p<0.01). BAV and MVP patients had more intracardiac complications than low/moderate-risk group (50% and 47.2% vs 30.6%, both p<0.01) and similar to high-risk group patients.
Conclusions: IE in patients with BAV and MVP have higher rates of VGS IE and IE from suspected odontological origin than in other IE patients, with a clinical profile similar to that of high-risk IE patients. Our findings suggest that BAV and MVP should be classified as high-risk IE conditions and the case for IEAP should be reconsidered.pre-print769 K
Stability of Ampicillin plus Ceftriaxone Combined in Elastomeric Infusion Devices for Outpatient Parenteral Antimicrobial Therapy
Ampicillin; Infective endocarditis; Outpatient parenteral antimicrobial therapyAmpicil·lina; Endocarditis infecciosa; TerĂ pia antimicrobiana parenteral ambulatĂČriaAmpicilina; Endocarditis infecciosa; Terapia antimicrobiana parenteral ambulatoriaCurrently, ampicillin plus ceftriaxone (AC) is one of the preferred treatments for Enterococcus faecalis infective endocarditis. However, there is a lack of stability data for the combination of both drugs in elastomeric devices, so the inclusion of AC in Outpatient Parenteral Antimicrobial Therapy (OPAT) programs is challenging. The objective of the study was to determine the stability of AC in elastomeric pumps when stored at 8 ± 2 °C, 25 ± 2 °C, 30 ± 2 °C and 37 ± 2 °C using LC-MS/MS. The combination was diluted in 0.9% sodium chloride and the final concentrations were ampicillin 24 g/L plus ceftriaxone 8 g/L. Physical and chemical stability were evaluated at 12, 20, 24, 36 and 48 h after preparation. Stability was met at each time point if the percentage of intact drug was â„90% of its respective baseline concentration and color and clearness remained unchanged. The drug combination was stable for 48 h when it was kept at 8 ± 2 °C. At 25 ± 2 °C and 30 ± 2 °C, they were stable for 24 h of storage. At 37 ± 2 °C, the stability criterion was not met at any time point. These results prove that AC could be included in OPAT programs using elastomeric infusion devices for the treatment of E. faecalis infections.This work was supported by the Sociedad Española de Farmacia Hospitalaria and the AFinf Working Group for the project âStability study of antimicrobials under conditions analogous to the outpatient parenteral antibiotic therapy program (OPAT)â. A.G.-V. was supported by the Instituto de Salud Carlos III, co-financed by the European Development Regional Fund (âA way to achieve Europeâ), Subprograma Miguel Servet (grant CP19/00159). L.H.-H. was supported by the Instituto de Salud Carlos III, co-financed by the European Development Regional Fund (âA way to achieve Europeâ), Subprograma Juan RodĂ©s (grant JR22/00049)
Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort
Staphylococcus aureus; Bacteremia; Outpatient parenteral antimicrobial therapyStaphylococcus aureus; BacteriĂšmia; TerĂ pia antimicrobiana parenteral ambulatĂČriaStaphylococcus aureus; Bacteriemia; Terapia antimicrobiana parenteral ambulatoriaIt is not known whether sequential outpatient parenteral antimicrobial (OPAT) is as safe and effective as conventional hospitalization in patients with S. aureus bacteremia (SAB). A post-hoc analysis of the comparative effectiveness of conventional hospitalization versus sequential OPAT was performed in two prospective Spanish cohorts of patients with S. aureus bacteremia. The PROBAC cohort is a national, multicenter, prospective observational cohort of patients diagnosed in 22 Spanish hospitals between October 2016 and March 2017. The DOMUS OPAT cohort is a prospective observational cohort including patients from two university hospitals in Seville, Spain from 2012 to 2021. Multivariate regression was performed, including a propensity score (PS) for receiving OPAT, stratified analysis according to PS quartiles, and matched pair analyses based on PS. Four hundred and thirteen patients were included in the analysis: 150 in sequential OPAT and 263 in the full hospitalization therapy group. In multivariate analysis, including PS and center effect as covariates, 60-day treatment failure was lower in the OPAT group than in the full hospitalization group (p < 0.001; OR 0.275, 95%CI 0.129â0.584). In the PS-based matched analyses, sequential treatment under OPAT was not associated with higher 60-day treatment failure (p = 0.253; adjusted OR 0.660; % CI 0.324â1.345). OPAT is a safe and effective alternative to conventional in-patient therapy for completion of treatment in well-selected patients with SAB, mainly those associated with a low-risk source and without end-stage kidney disease
Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT
Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus
(MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT)
programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day
(Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective
observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The
primary outcome was treatment success, defined as completing the antimicrobial regimen without
death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and
multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically
significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients
were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned
readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491).
There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to
Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered
every two days through an OPAT program is not associated with an increased risk of treatment
failure and entails a significant reduction in resource consumption compared to daily delivery
Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis
Ampicillin plus ceftriaxone combined therapy for enterococcus faecalis infective endocarditis in opat
Ampicillin plus ceftriaxone (AC) is a well-recognized inpatient regimen for Enterococcus
faecalis infective endocarditis (IE). In this regimen, ceftriaxone is usually administered 2 g every 2 h
(AC12). The administration of AC in outpatient parenteral antibiotic treatment (OPAT) programs
is challenging because multiple daily doses are required. AC regimens useful for OPAT programs
include once-daily high-dose administration of ceftriaxone (AC24) or AC co-diluted and jointly
administered in bolus every 4 h (ACjoined). In this retrospective analysis of prospectively collected
cases, we aimed to assess the clinical effectivity and safety of three AC regimens for the treatment
of E. faecalis IE. Fifty-nine patients were treated with AC combinations (AC12 n = 32, AC24 n = 17,
and ACjoined n = 10). Six relapses occurred in the whole cohort: five (29.4%) treated with AC24
regimen and one (10.0%) with ACjoined. Patients were cured in 30 (93.3%), 16 (94.1%), and eight
(80.0%) cases in the AC12, AC24 and ACjoined groups, respectively. Unplanned readmission occurred
in eight (25.0%), six (35.3%), and two (20.0%) patients in the AC12, AC24 and ACjoined groups,
respectively. The outcome of patients with E. faecalis IE treated with AC in OPAT programs relies
on an optimization of the delivery of the combination. AC24 exhibit an unexpected rate of failures,
however, ACjoined might be an effective alternative which clinical results should corroborate in
further studies
Mural Endocarditis: The GAMES Registry Series and Review of the Literature
Introduction Mural infective endocarditis (MIE) is a rare type of endovascular infection. We present a comprehensive series of patients with mural endocarditis.
Method sPatients with infectious endocarditis (IE) from 35 Spanish hospitals were prospectively included in the GAMES registry between 2008 and 2017. MIEs were compared to non-MIEs. We also performed a literature search for cases of MIE published between 1979 and 2019 and compared them to the GAMEs series.
Results Twenty-seven MIEs out of 3676 IEs were included. When compared to valvular IE (VIE) or device-associated IE (DIE), patients with MIE were younger (median age 59 years, pâ<â0.01). Transplantation (18.5% versus 1.6% VIE and 2% DIE, pâ<â0.01), hemodialysis (18.5% versus 4.3% VIE and 4.4% DIE, pâ=â0.006), catheter source (59.3% versus 9.7% VIE and 8.8% DIE, pâ<â0.01) and Candida etiology (22.2% versus 2% DIE and 1.2% VIE, pâ<â0.01) were more common in MIE, whereas the Charlson Index was lower (4 versus 5 in non-MIE, pâ=â0.006). Mortality was similar.MIE from the literature shared many characteristics with MIE from GAMES, although patients were younger (45 years vs. 56 years, pâ<â0.001), the Charlson Index was lower (1.3 vs. 4.3, pâ=â0.0001), catheter source was less common (13.9% vs. 59.3%) and there were more IVDUs (25% vs. 3.7%). S. aureus was the most frequent microorganism (50%, pâ=â0.035). Systemic complications were more common but mortality was similar.
Conclusion MIE is a rare entity. It is often a complication of catheter use, particularly in immunocompromised and hemodialysis patients. Fungal etiology is common. Mortality is similar to other IEs
Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study
Streptococcus anginosus; Endocarditis infecciosa; Estreptococs del grup viridansStreptococcus anginosus; Endocarditis infecciosa; Estreptococos del grupo viridansStreptococcus anginosus; Infective endocarditis; Viridans group streptococciBackground
Although Streptococcus anginosus group (SAG) endocarditis is considered a severe disease associated with abscess formation and embolic events, there is limited evidence to support this assumption.
Methods
We performed a retrospective analysis of prospectively collected data from consecutive patients with definite SAG endocarditis in 28 centers in Spain and Italy. A comparison between cases due to SAG endocarditis and viridans group streptococci (VGS) or Streptococcus gallolyticus group (SGG) was performed in a 1:2 matched analysis.
Results
Of 5336 consecutive cases of definite endocarditis, 72 (1.4%) were due to SAG and matched with 144 cases due to VGS/SGG. SAG endocarditis was community acquired in 64 (88.9%) cases and affected aortic native valve in 29 (40.3%). When comparing SAG and VGS/SGG endocarditis, no significant differences were found in septic shock (8.3% vs 3.5%, Pâ
=â
.116); valve disorder, including perforation (22.2% vs 18.1%, Pâ
=â
.584), pseudoaneurysm (16.7% vs 8.3%, Pâ
=â
.108), or prosthesis dehiscence (1.4% vs 6.3%, Pâ
=â
.170); paravalvular complications, including abscess (25% vs 18.8%, Pâ
=â
.264) and intracardiac fistula (5.6% vs 3.5%, Pâ
=â
.485); heart failure (34.7% vs 38.9%, Pâ
=â
.655); or embolic events (41.7% vs 32.6%, Pâ
=â
.248). Indications for surgery (70.8% vs 70.8%; Pâ
=â
1) and mortality (13.9% vs 16.7%; Pâ
=â
.741) were similar between groups.
Conclusions
SAG endocarditis is an infrequent but serious condition that presents a prognosis similar to that of VGS/SGG.This work was supported by Plan Nacional de I+D+i 2013â2016 and Instituto de Salud Carlos III, SubdirecciĂłn General de Redes y Centros de InvestigaciĂłn Cooperativa, Ministerio de Ciencia, InnovaciĂłn y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), coâfinanced by the European Development Regional Fund âA way to achieve Europe,â Operative Program Intelligent Growth 2014â2020. We thank CERCA Programme/Generalitat de Catalunya for institutional support. J. M. M. received a personal 80:20 research grant from Institut dâInvestigacions BiomĂšdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017â2021
Infective endocarditis in patients with heart transplantation
[Background] The incidence of nosocomial and health care-related infective endocarditis (IE) is increasing. Heart transplantation (HT) implies immunosuppression and frequent health care contact. Our aim was to describe the current profile and prognosis of IE in HT recipients.[Methods] Multicenter retrospective registry-based study in Spain and France that included cases between 2008 and 2019.[Results] During the study period, 8305 HT were performed in Spain and France. We identified 18 IE cases (rate 0.2%). Median age was 57 years; 12 were men (67%). Valve involvement did not have a predominant location and three patients (16.7%) had atrial or ventricular vegetations without valve involvement. The median age-adjusted Charlson index was 4 (interquartile range 3â5). Eleven IE cases (61%) were nosocomial/health care-related. Median time (range) between HT and development of IE was 43 months (interquartile range 6â104). The major pathogens were Staphylococcus sp. (n = 8, 44%), Enterococcus sp. (n = 4, 22%), and Aspergillus sp. (n = 3, 17%). Although eight patients (44%) had a surgical indication, it was only performed in three cases (17%). Three patients (17%) died during the first IE hospital admission.[Conclusions] IE in HT recipients has specific characteristics. Valve involvement does not have a predominant location and non-valvular involvement is common. Three fifths have a nosocomial/health care-related origin. The major pathogens were staphylococci (44%), enterococci (22%), and Aspergillus (17%). In-hospital mortality was 17%.Peer reviewe
Blood culture-negative infective endocarditis: a worse outcome? Results from a large multicentre retrospective Spanish cohort study
[Background] To assess the impact of blood cultures negative infective endocarditis (BCNIE) on in-hospital mortality.[Methods] Prospective multicentre study with retrospective analysis of a Spanish cohort including adult patients with definite IE. Cardiac implantable devices infection were excluded. Comparisons between blood cultures positive and BCNIE groups were performed to analyse in-hospital mortality.[Results] 1001 cases were included of which 83 (8.3%) had BCNIE. Alternative microbiological diagnosis was achieved for 39 (47%) out 83 cases. The most frequent identifications were: Coxiella burnetii (11; 28.2%), Tropheryma whipplei (4; 10.3%), Streptococcus gallolyticus (4;10.3%) and Staphylococcus epidermidis (3; 7.7%). Surgery was performed more frequently in BCNIE group (57.8 vs. 36.9%, pâ<â.001). All-cause in-hospital mortality rate was 26.7% without statistical difference between compared groups. BCNIE was not associated to worse mortality rate in Cox regression model (aHR = 1.37, 95% CI 0.90â2.07, pâ=â.14). Absence of microbiological diagnosis was also not associated to worse in-hospital prognosis (aHR = 1.62, 95% CI 0.99â2.64, pâ=â.06).[Conclusions] In our cohort, BCNIE was not associated to greater in-hospital mortality based in multivariate Cox regression models. The variables most frequently associated with mortality were indicated but not performed surgery (aHR = 2.48, 95% CI 1.73â3.56, pâ<â.001), septic shock (aHR = 2.24, 95% CI 1.68â2.99, pâ<â.001), age over 65âyears (aHR = 1.88, 95% CI 1.40-2.52, pâ<â.001) and complicated endocarditis (aHR = 1.79, 95% CI 1.36â2.37, pâ<â.001).Peer reviewe
- âŠ